AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00658086
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by nebulization once daily for 3 days
Trial: NCT02001285
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
Trial: NCT01829243
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02577393
Drug: mLDG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mLDG (lidocaine 0.16mg/mL, dexamethasone 0.02mg/mL, and gentamycin 0.16mg/mL) dissolved in 0.9% saline solution was administered three times a day. Patients were given oral mLDG solution, and began medications as soon as grade 1 esophagitis occurred during radiation according to the RTOG criterion.
Trial: NCT00769132
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets for each of the interventions once daily for 7 days
Trial: NCT00960232
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00189410
Drug: Pegylated Liposomal Doxorubicin and Carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04140123
Drug: ZSP1601
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZSP1601 tablets be taken orally for 28 days.
Trial: NCT04140123
Drug: ZSP1601 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive matching placebo of ZSP1601
Trial: NCT00366093
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet
Trial: NCT00949767
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Matching volume) - Oral Solution, Oral, once 14 days
Trial: NCT01802918
Drug: GSK2838232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
Trial: NCT01802918
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visually matching GSK2838232
Trial: NCT01715597
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
Trial: NCT01715597
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 500ml IV
Trial: NCT00647829
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
Trial: NCT00647829
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
Trial: NCT00647829
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet by mouth for 2 doses over a 24-hour period
Trial: NCT03652805
Drug: IPL344
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study is designed to determine the tolerability, safety and PK of IPL344 administered I.V. once a day for 28 days and to identify the maximum tolerated dose.~All patients enrolled will have a documented history of ALS disease prior to study enrollment.~Treatment will start with 1.7mg/kg with dose escalation by 0.5 mg/kg every 3-4 days and will increase to the maximum dose of 3.2mg/kg. Day 1 to Day 28 patients will be on active treatment.~After completion of 28 treatment days, participants who will choose to continue treatment (at the investigator's discretion), will be enrolled in a follow-up study. Participants that discontinue treatment after Day 28 will be followed up by a nurse phone call and return to the clinic for a final visit on Day 56 from the first dose.
Trial: NCT04038840
Drug: [11C]UCB-J radiotracer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.V. bolus administration of up to 15 mCi (equivalent to 0.3 rems) in the antecubital vein
Trial: NCT01997112
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00214604
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg
Trial: NCT00214604
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20mg
Trial: NCT03733418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo that matched the vitamin D3 color was provided.
Trial: NCT00214604
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg
Trial: NCT01765478
Drug: HM71224 single ascending dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765478
Drug: HM71224 food effect
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00223236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching active medication in all other aspects.
Trial: NCT00331604
Drug: inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat-to-target dose titration scheme, inhalation.
Trial: NCT02499445
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administering remifentanil for anesthesia maintenance
Trial: NCT02499445
Drug: sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administering sufentanil for anesthesia maintenance
Trial: NCT00000485
Drug: diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000485
Drug: antihypertensive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00553722
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
Trial: NCT00553722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer a placebo tablet orally twice daily for 4 weeks.
Trial: NCT04320030
Drug: [18F]-DPA-714 PET/CT scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pretherapeutic \[18F\]-DPA-714 PET/CT scan
Trial: NCT03602560
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily
Trial: NCT00877799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered the day after surgery (Day 1)
Trial: NCT00877799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo administered immediately after surgery (Day 0)
Trial: NCT00340574
Drug: AMA1-C1/Alhydrogel + CpG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216812
Drug: 500 mg vitamin c, 1 pill per day for 6 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02216812
Drug: 1 placebo pill for 6 weeks
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00129311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00595127
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (10mg/kg/day x 4days)
Trial: NCT02111265
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.~2. Remifentanil is stopped before skin closure
Trial: NCT02111265
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
Trial: NCT00649597
Drug: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
RxNorm normalized name: benazepril hydrochloride / hydrochlorothiazide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fasting
Trial: NCT00649597
Drug: Lotensin HCT® Tablets 20 mg/25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20/25mg, single dose fasting
Trial: NCT01510457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
Trial: NCT02070198
Drug: Long acting FSH and GnRH antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
Trial: NCT01569074
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 12 weeks
Trial: NCT02070198
Drug: Daily FSH and GnRH antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
Trial: NCT02880956
Drug: placebo for ABBV-8E12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo solution for intravenous (IV) infusion
Trial: NCT00080925
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00080925
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00545493
Drug: i.v. immunoglobulins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
Trial: NCT01833897
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
Trial: NCT00703261
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
Trial: NCT02989467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one placebo tablet daily for 5 consecutive days.
Trial: NCT01771809
Drug: 75mg SHP647 (PF-00547659)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg sterile liquid injected subcutaneously every 4 weeks.
Trial: NCT02634645
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical substances are used to treat cancer
Trial: NCT03490539
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablet
Trial: NCT01215929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
Trial: NCT02776748
Drug: FTC/TDF PrEP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
Trial: NCT00003296
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04088630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral placebo pill within 24 hours of symptom onset
Trial: NCT00057980
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00866008
Drug: Ovarian stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment~2. Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG.
Trial: NCT04810728
Drug: Extract Psidii guava
RxNorm normalized name: guava extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Capsule Extract Psidii guava, three times daily
Trial: NCT03470532
Drug: buccal infiltration of 4% Articaine with Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Articaine Hydrochloride 4 % / Epinephrine 1:200,000 1.8 ML Cartridge
Trial: NCT03470532
Drug: buccal infiltration of 2% Mepivacaine with Epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepivacaine Hydrochloride 2% Epinephrine 1:200,000 2.2 Ml Cartridge
Trial: NCT02793856
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To deplete Tregs before collecting peripheral blood
Trial: NCT03390101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Arm 3, patients will be given two SC injections of placebo (1.0 mL each) according to the following schedule: on Day 1 of weeks 0, 1, 2 and then once every 2 weeks through Week 10.~On Week 12, the treatment efficacy will be assessed with a PASI75 score, and the therapies will be unblinded. During the open-label period, patients from Arm 3 will receive BCD-085 at weeks 12, 13, 14 and then once every 4 weeks through week 50. The follow-up will continue through week 54.
Trial: NCT03175029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered orally twice per day after meals, for 12 weeks.
Trial: NCT00102778
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02527200
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
Trial: NCT06365762
Drug: EDTA Ophthalmic Solution 2.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06365762
Drug: EDTA Ophthalmic Solution 1.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02171910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
Trial: NCT03740893
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.
Trial: NCT02654964
Drug: Combination Drug Therapy
RxNorm normalized name: BILE THERAPY DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:~Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent
Trial: NCT02350751
Drug: MEDI8852
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02350751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03315754
Drug: TOOKAD Soluble 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular targeted photodynamic therapy using TOOKAD Soluble
Trial: NCT01271582
Drug: Irinotecan, 5FU, leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI regimen every 2 weeks \[irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)\]
Trial: NCT03859973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT03842982
Drug: HIPEC
RxNorm normalized name: Hyperthermic Intraperitoneal Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC protocol (ONLY Arm A) consisted in cisplatin 100mg/m2 intraperitoneally (IP), heated to 40°C for 90 minutes, along with an IV perfusion of sodium thiosulfate.~Administration of the dose should be according the following schedule:~* 50% of the dose at start of perfusion, 25% of the dose after 30 minutes from start of the perfusion and 25% of the dose after 60 minutes from start of the perfusion.~* The procedure takes 120 minutes with a 90-minute perfusion period. The IV perfusion of sodium thiosulfate is for renal protection. At the start of HIPEC procedure, 9 g/m2 in 200 ml of distilled water will be administered by IV over 15 to 30 minutes. It will be then followed by 12 g/m2 in 1 liter (1L) distilled water in a continuous IV for 6 hours.
Trial: NCT01331213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01160419
Drug: Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/m², 1-2-hour-Infusion, day 1
Trial: NCT01160419
Drug: 5-FU 2600 mg/m², 24-hour-Infusion, day 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2600 mg/m², 24-hour-Infusion, day 1
Trial: NCT04015375
Drug: ACZONE® (dapsone) gel, 7.5% (Allergan, INC.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel
Trial: NCT01369329
Drug: Group 1: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=intravenous use, in a single dose.
Trial: NCT03206788
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, matching the Losartan intervention, taken by mouth daily in the morning for week 1 followed by twice daily (one in the morning and one in the evening) on Weeks 2-12.
Trial: NCT02811523
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin by In Vivo Lung Perfusion
Trial: NCT00650481
Drug: Ditropan XL® Tablets 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4x5mg, single dose fasting
Trial: NCT00645255
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo one capsule daily
Trial: NCT00335985
Drug: Placebo of GB-0998
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL/kg per day is intravenously administered for five successive days
Trial: NCT00884767
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00884767
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00884767
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00940472
Drug: DMMET-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
Trial: NCT02163278
Drug: DBPR108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
Trial: NCT02163278
Drug: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
Trial: NCT00838864
Drug: ceftrioxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg iv q12h for 3 days
Trial: NCT00838864
Drug: ceftrioxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg q12h for 7 days
Trial: NCT03782831
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection every 2 weeks